What corticosteroid regimen should be used for symptomatic relief of Sydenham's chorea in children or adolescents, including dosing, taper, and alternatives?

Corticosteroids for Sydenham's Chorea

Corticosteroids should be used as first-line immunotherapy for moderate to severe Sydenham's chorea, with treatment duration of 1-3 months depending on severity, and are recommended to shorten chorea duration and reduce relapse risk. 1

Indications for Corticosteroid Therapy

The 2025 international consensus guidelines provide clear severity-based recommendations 1:

• Mild SC (symptoms present without causing disability): Immunotherapy may not be required
• Moderate SC: Corticosteroids should be considered
• Severe SC (bedridden, unable to take independent steps, severe generalized hypotonia): Corticosteroids should be strongly considered

This severity-stratified approach is supported by meta-analysis data showing corticosteroids reduce chorea duration (median 1.2 months vs 2.8 months without treatment, p=0.004) and significantly decrease relapse risk (OR 0.32,95% CI 0.15-0.67) 2.

Corticosteroid Regimen Options

The consensus guidelines recommend several equivalent options 1:

Severe cases:

• IV methylprednisolone followed by oral deflazacort
• Alternatively: IV dexamethasone followed by oral continuation
• Alternatively: Oral prednisolone/prednisone alone

Moderate cases:

• Oral deflazacort, prednisolone, or prednisone

Specific Dosing Recommendations

While the guidelines reference Table 3 for specific doses 1, the research literature provides practical regimens:

• IV methylprednisolone: Used in severe/paralytic cases, typically followed by oral therapy 3, 4
• Oral prednisone: Effective in both moderate and severe cases, showing faster improvement (4 vs 16 days) and shorter remission time (30 vs 135 days) compared to no treatment 5
• Deflazacort: Well-tolerated with no significant side effects reported in multiple studies 3, 4

Treatment Duration and Taper

Duration: 1-3 months based on disease severity 1

The evidence strongly supports this duration:

• Patients receiving ≥1 month of corticosteroids had significantly lower odds of relapsing course (OR 0.10,95% CI 0.04-0.25, p<0.001) 2
• Treatment for less than 1 month appears insufficient to prevent relapse

Response Timeline and Escalation

Expected response:

• Improvement in swallowing/chewing: 2-3 days after starting IV methylprednisolone 3
• Complete disappearance of movement disorders: 3-4 weeks 3
• Faster clinical improvement: 4 days vs 16 days without steroids 5

If inadequate recovery within 2-4 weeks of corticosteroid therapy:

• Add IV immunoglobulin or plasma exchange as second-line immunotherapy 1
• Second-line agents (rituximab, cyclophosphamide) are generally not recommended 1

Alternative First-Line Immunotherapy

If corticosteroids are contraindicated: Use IV immunoglobulin as alternative first-line immunotherapy 1

Critical Caveats

Evidence Quality Limitations

The guidelines explicitly acknowledge that corticosteroid recommendations are based on one small randomized controlled trial, observational data, and meta-analysis—the quality of evidence is not strong 1. The planned TREAT-SC study (NCT06259006) aims to clarify optimal immunotherapy use across severity levels.

Concurrent Essential Treatments

Corticosteroids must be combined with:

• Antibiotic treatment at first presentation 1
• Long-term secondary antibiotic prophylaxis following international/local guidelines 1
• Antibiotics independently reduce relapse risk (OR 0.28,95% CI 0.09-0.85) 2

Relapse Management

For SC relapse: Repeat corticosteroid therapy should be considered alongside clinical reassessment, etiological investigation, and antibiotics 1

Safety Profile

Multiple studies report excellent tolerability with deflazacort and prednisolone, with weight gain being the primary side effect noted 3, 4, 6. No significant adverse events were reported in the observational studies reviewed.

Practical Algorithm

1. Assess severity (mild/moderate/severe based on functional disability)
2. Mild SC: Consider symptomatic treatment alone; monitor closely
3. Moderate-Severe SC: Initiate corticosteroids
   • Severe: IV methylprednisolone → oral deflazacort/prednisolone
   • Moderate: Oral deflazacort or prednisolone
4. Duration: 1-3 months (longer for severe cases)
5. Reassess at 2-4 weeks: If inadequate recovery → add IVIG or plasma exchange
6. Always combine with: Antibiotics at presentation + long-term prophylaxis

The 2025 consensus guidelines represent the most authoritative and recent evidence, though they acknowledge the need for higher-quality randomized trials to definitively establish optimal corticosteroid protocols 1.